Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. has utilized its Deep Docking AI platform to rapidly identify promising drug candidates for cancer treatment, a process that traditionally would take thousands of years. The company plans to validate these candidates and aims to advance a best-in-class drug candidate to human trials.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
